CAMAP: Artificial neural networks unveil the role of codon arrangement in modulating MHC-I peptides presentation.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
10 2021
Historique:
received: 13 02 2021
accepted: 27 09 2021
revised: 09 11 2021
pubmed: 23 10 2021
medline: 15 12 2021
entrez: 22 10 2021
Statut: epublish

Résumé

MHC-I associated peptides (MAPs) play a central role in the elimination of virus-infected and neoplastic cells by CD8 T cells. However, accurately predicting the MAP repertoire remains difficult, because only a fraction of the transcriptome generates MAPs. In this study, we investigated whether codon arrangement (usage and placement) regulates MAP biogenesis. We developed an artificial neural network called Codon Arrangement MAP Predictor (CAMAP), predicting MAP presentation solely from mRNA sequences flanking the MAP-coding codons (MCCs), while excluding the MCC per se. CAMAP predictions were significantly more accurate when using original codon sequences than shuffled codon sequences which reflect amino acid usage. Furthermore, predictions were independent of mRNA expression and MAP binding affinity to MHC-I molecules and applied to several cell types and species. Combining MAP ligand scores, transcript expression level and CAMAP scores was particularly useful to increase MAP prediction accuracy. Using an in vitro assay, we showed that varying the synonymous codons in the regions flanking the MCCs (without changing the amino acid sequence) resulted in significant modulation of MAP presentation at the cell surface. Taken together, our results demonstrate the role of codon arrangement in the regulation of MAP presentation and support integration of both translational and post-translational events in predictive algorithms to ameliorate modeling of the immunopeptidome.

Identifiants

pubmed: 34679099
doi: 10.1371/journal.pcbi.1009482
pii: PCOMPBIOL-D-21-00287
pmc: PMC8577786
doi:

Substances chimiques

Codon 0
Histocompatibility Antigens Class I 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009482

Subventions

Organisme : CIHR
ID : 148936
Pays : Canada
Organisme : CIHR
ID : 163051
Pays : Canada
Organisme : CIHR
ID : MOP-133726
Pays : Canada

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6020-4
pubmed: 1378619
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Nat Rev Genet. 2011 Jan;12(1):32-42
pubmed: 21102527
Genome Med. 2019 Apr 30;11(1):29
pubmed: 31039809
PLoS One. 2011;6(4):e18556
pubmed: 21602908
J Clin Invest. 2016 Dec 1;126(12):4690-4701
pubmed: 27841757
Nat Commun. 2016 Jan 05;7:10238
pubmed: 26728094
Mol Syst Biol. 2011 Sep 27;7:533
pubmed: 21952136
J Mol Evol. 2001 Oct-Nov;53(4-5):290-8
pubmed: 11675589
Cell. 2010 Apr 16;141(2):355-67
pubmed: 20403329
Immunogenetics. 2005 Apr;57(1-2):33-41
pubmed: 15744535
Nature. 2015 May 28;521(7553):436-44
pubmed: 26017442
Nat Rev Immunol. 2011 Nov 11;11(12):823-36
pubmed: 22076556
J Leukoc Biol. 2014 Apr;95(4):551-62
pubmed: 24532645
J Proteome Res. 2017 Apr 7;16(4):1806-1816
pubmed: 28244318
J Immunol. 2016 Sep 15;197(6):2492-9
pubmed: 27511729
Nucleic Acids Res. 2010 May;38(9):2964-74
pubmed: 20097653
J Immunol. 1993 Apr 1;150(7):2724-36
pubmed: 8454852
Annu Rev Immunol. 2007;25:681-95
pubmed: 17291190
Cell Mol Life Sci. 2005 May;62(9):1025-37
pubmed: 15868101
J Immunol. 1996 Sep 1;157(5):1823-6
pubmed: 8757297
PLoS Pathog. 2013 Jan;9(1):e1003129
pubmed: 23382674
Curr Opin Immunol. 2003 Aug;15(4):461-70
pubmed: 12900280
Elife. 2015 Jul 08;4:
pubmed: 26154972
Immunity. 2017 Feb 21;46(2):315-326
pubmed: 28228285
Elife. 2019 Dec 19;8:
pubmed: 31855182
J Immunol. 2019 Jun 15;202(12):3370-3380
pubmed: 31092636
Leukemia. 2016 Jun;30(6):1344-54
pubmed: 26857467
F1000Res. 2016 Mar 21;5:381
pubmed: 27785359
Nat Rev Mol Cell Biol. 2018 Jan;19(1):20-30
pubmed: 29018283
Mol Cell Proteomics. 2006 Feb;5(2):357-65
pubmed: 16272561
Sci Transl Med. 2018 Dec 5;10(470):
pubmed: 30518613
Curr Opin Immunol. 2017 Jun;46:58-65
pubmed: 28478383
Mol Cell. 2019 Mar 21;73(6):1162-1173.e5
pubmed: 30712990
Methods Mol Biol. 2019;1988:109-122
pubmed: 31147936
Mol Cell Proteomics. 2013 Sep;12(9):2394-407
pubmed: 23674617
Genome Med. 2016 Mar 30;8(1):33
pubmed: 27029192
Mol Cell Proteomics. 2013 Jul;12(7):1829-43
pubmed: 23481700
PLoS Comput Biol. 2020 May 26;16(5):e1007757
pubmed: 32453790
Curr Opin Immunol. 2015 Jun;34:1-8
pubmed: 25466393
Nat Methods. 2009 May;6(5):343-5
pubmed: 19363495

Auteurs

Tariq Daouda (T)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.
Department of Biochemistry, Université de Montréal, Montréal, Canada.

Maude Dumont-Lagacé (M)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.
Department of Medicine, Université de Montréal, Montréal, Canada.

Albert Feghaly (A)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.

Yahya Benslimane (Y)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.
Department of Medicine, Université de Montréal, Montréal, Canada.

Rébecca Panes (R)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.
Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, Canada.

Mathieu Courcelles (M)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.

Mohamed Benhammadi (M)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.
Department of Medicine, Université de Montréal, Montréal, Canada.

Lea Harrington (L)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.
Department of Medicine, Université de Montréal, Montréal, Canada.

Pierre Thibault (P)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.
Department of Chemistry, Université de Montréal, Montréal, Canada.

François Major (F)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.
Department of Computer Science and Operations Research, Université de Montréal, Montréal, Canada.

Yoshua Bengio (Y)

Department of Computer Science and Operations Research, Université de Montréal, Montréal, Canada.

Étienne Gagnon (É)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.
Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, Canada.

Sébastien Lemieux (S)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.
Department of Biochemistry, Université de Montréal, Montréal, Canada.
Department of Computer Science and Operations Research, Université de Montréal, Montréal, Canada.

Claude Perreault (C)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.
Department of Medicine, Université de Montréal, Montréal, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH